McGill Pharmacoepidemiology Research Unit, Center for clinical epidemiology, Jewish General Hospital, Department of Epidemiology and Biostatistics, McGill University, Montreal, Canada H3T 1E2.
BMJ. 2010 Jun 3;340:c2519. doi: 10.1136/bmj.c2519.
To determine the risk of stroke associated with oral and transdermal routes of administration of hormone replacement therapy.
Population based nested case-control study. Setting About 400 general practices in the United Kingdom contributing to the General Practice Research Database. Participants Cohort of all women in the database aged 50-79 years between 1 January 1987 and 31 October 2006 who were members of a practice that fulfilled predefined quality criteria and without a diagnosis of stroke before cohort entry. For each case of stroke occurring during follow-up, up to four controls were selected from among the cohort members in the risk sets defined by the case. Exposure to hormone replacement therapy (HRT) was categorised into oestrogens only, oestrogens plus progestogen, progestogen only, and tibolone. Oestrogens were further subdivided according to the route of administration (oral v transdermal) and dose (high v low). Main outcome measures Rate ratio of stroke associated with current use of oral and transdermal HRT compared with no use. Current use was considered as a prescription whose duration included the index date.
There were 15,710 cases of stroke matched to 59 958 controls. The rate of stroke in the cohort was 2.85 per 1000 per year. The adjusted rate ratio of stroke associated with current use of transdermal HRT was 0.95 (95% CI 0.75 to 1.20) relative to no use. The risk of stroke was not increased with use of low oestrogen dose patches (rate ratio 0.81(0.62 to 1.05)) compared with no use, whereas the risk was increased with high dose patches (rate ratio 1.89 (1.15 to 3.11)). Current users of oral HRT had a higher rate of stroke than non-users (rate ratio 1.28 (1.15 to 1.42)) with both low dose and high dose.
The use of transdermal HRT containing low doses of oestrogen does not seem to increase the risk of stroke. The presence of residual confounding, however, cannot be entirely excluded in the interpretation of this finding.
确定与激素替代疗法的口服和透皮给药途径相关的中风风险。
基于人群的巢式病例对照研究。
英国约 400 家参与一般实践研究数据库的普通诊所。
数据库中所有年龄在 50-79 岁之间的女性,她们在 1987 年 1 月 1 日至 2006 年 10 月 31 日期间是符合规定质量标准的实践成员,并且在队列入组前没有中风诊断。对于随访期间发生的每例中风病例,从病例定义的风险组中选择最多 4 名队列成员作为对照。激素替代疗法(HRT)的暴露分为仅雌激素、雌激素加孕激素、孕激素和替勃龙。根据给药途径(口服与透皮)和剂量(高与低)进一步细分雌激素。
与未使用相比,当前使用口服和透皮 HRT 与中风相关的比率。当前使用被认为是一种持续时间包括索引日期的处方。
有 15710 例中风病例与 59958 例对照相匹配。队列中中风的发生率为每年每 1000 人 2.85 例。与未使用相比,当前使用透皮 HRT 与中风相关的调整后比值比为 0.95(95%CI 0.75 至 1.20)。与未使用相比,使用低雌激素剂量贴片不会增加中风风险(比值比 0.81(0.62 至 1.05)),而使用高剂量贴片会增加中风风险(比值比 1.89(1.15 至 3.11))。与未使用者相比,当前使用口服 HRT 的患者中风发生率更高(比值比 1.28(1.15 至 1.42)),且低剂量和高剂量均如此。
使用含有低剂量雌激素的透皮 HRT 似乎不会增加中风风险。然而,在解释这一发现时,不能完全排除残留混杂因素的存在。